Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
4 D1 r) F) D+ v+ A3 O
/ T9 F" Q1 v V: d- y7 z9 m
0 k* @# N- d7 I+ y* wSub-category:
1 H' _7 y; D; ] k4 c3 cMolecular Targets
4 x. P. `- N5 n2 B* U: Q
$ z7 S& N9 v, _) a3 [# e8 E$ q5 r+ r6 `' J+ T2 S
Category:: ?" K2 `4 X* e- l& \3 W
Tumor Biology 3 q+ m a9 V! z. q6 r
4 r) S9 ^! a# H8 Q
% A0 P# a( O$ U" KMeeting:
! v8 p' {2 ]) S" [2011 ASCO Annual Meeting
( l% u d" b/ k& h1 ?: Q# f% C
! y# N, y. G/ L% `- C; R$ j- M$ [6 p& H1 Z
Session Type and Session Title:
; ] n" B' D$ t4 k- y }( aPoster Discussion Session, Tumor Biology % Z8 X! F& d3 t* K' Y; `6 O" a, D
/ J. e% ~/ {: E5 S+ B7 U8 i
0 T* Y. X _5 o# W
Abstract No:# `) _9 x3 O% ~+ D: P0 [
10517 * e# z, C- ?8 f
/ E4 k9 v$ j3 s$ E5 ~# b* j1 P" P
: |* a5 a/ U$ r5 M
Citation:
% W4 x8 f" y/ |J Clin Oncol 29: 2011 (suppl; abstr 10517)
1 K/ H1 M3 @0 ]+ x) U0 G& a5 \* J0 p& f( l5 u5 G0 G2 O
* H' P+ h" J) s7 E- X4 tAuthor(s):
) E) m$ B _4 F' _, |4 _$ @J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China . V s- h4 Z' r3 _
/ Q' L R5 H8 t& d7 [+ v3 U8 s
! j2 [/ p' @6 V/ M; A( r6 r
, t( c# O: U* v4 OAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
3 K& @5 C; r( a C8 j! o# d/ Y/ c
% ^5 s4 M! e6 c: F9 Y4 iAbstract Disclosures) B0 S/ o7 x% u! ^3 J% g; ?
2 @. f$ \- v, L; e$ V! S( w# h- f
Abstract:
# f# y: {% a7 B! z2 {/ M* `6 n7 D1 b
; U1 {/ y9 [/ {% q( ~
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.: @* \* q8 e, j/ F K- {
, a6 W- m4 T% r( C7 K
) Q$ `- B) Q* ~# O |
显身卡
